Education
About Us
Working with TipRanks
Follow Us
Roivant Sciences (ROIV)
NASDAQ:ROIV
ROIV Stock Chart & Stats
$27.67
-$0.41(-3.60%)
At close: 4:00 PM EST
$27.67
-$0.41(-3.60%)
Day’s Range― - ―
52-Week Range$8.73 - $25.95
Previous CloseN/A
Volume1.46M
Average Volume (3M)5.92M
Market Cap
$17.96B
Enterprise Value$17.97B
Total Cash (Recent Filing)$4.53B
Total Debt (Recent Filing)$207.44M
Price to Earnings (P/E)―
Beta0.80
Next Earnings
Jul 01, 2026EPS Estimate
-0.3Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.17
Shares Outstanding715,701,100
10 Day Avg. Volume6,802,707
30 Day Avg. Volume5,920,295
Financial Highlights & Ratios
PEG Ratio0.41
Price to Book (P/B)1.56
Price to Sales (P/S)251.93
P/FCF Ratio-8.67
Enterprise Value/Market Cap1.00
Enterprise Value/Revenue1.35K
Enterprise Value/Gross Profit1.48K
Enterprise Value/Ebitda-17.70
Forecast
1Y Price Target
$31.44Price Target Upside13.62% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering9
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Balance Sheet And Profitability PathwayAnalyst notes that the company's $4.4 billion cash position and management guidance to reduce operating expenses support a credible path to profitability and the ability to fund pivotal readouts and commercial launches.
Clinical Efficacy And Unmet NeedAnalyst highlights that brepocitinib produced rapid, clinically meaningful skin improvements in cutaneous sarcoidosis and showed consistent efficacy in dermatomyositis, positioning it as the only late-stage oral therapy for a patient population lacking FDA-approved treatments.
Regulatory Progression And Multi-indication PotentialAnalyst points out that an NDA submission in dermatomyositis together with ongoing Phase 3 development across multiple immune-mediated diseases supports the potential for several regulatory approvals and a multi-indication commercial franchise.
Bears Say
Clinical Trial Design RiskAnalyst cautions that faster steroid tapering protocols used in trials increase the risk of disease flares, which could complicate clinical outcomes and regulatory comparisons for brepocitinib.
Litigation And Cash-flow RiskAnalyst warns that ongoing litigation over lipid nanoparticle technology could produce a very large cash impact, introduce significant share volatility, and materially alter company valuation.
Readout Sensitivity And Valuation DownsideAnalyst notes that several pivotal programs appear largely priced into the shares, so disappointing clinical readouts or regulatory setbacks could trigger meaningful downside.
Roivant Sciences News
ROIV FAQ
What was Roivant Sciences’s price range in the past 12 months?
Roivant Sciences lowest stock price was $8.73 and its highest was $25.95 in the past 12 months.
What is Roivant Sciences’s market cap?
Roivant Sciences’s market cap is $17.96B.
When is Roivant Sciences’s upcoming earnings report date?
Roivant Sciences’s upcoming earnings report date is Jul 01, 2026 which is in 140 days.
How were Roivant Sciences’s earnings last quarter?
Roivant Sciences released its earnings results on Feb 06, 2026. The company reported -$0.17 earnings per share for the quarter, beating the consensus estimate of -$0.3 by $0.13.
Is Roivant Sciences overvalued?
According to Wall Street analysts Roivant Sciences’s price is currently Undervalued.
Does Roivant Sciences pay dividends?
Roivant Sciences does not currently pay dividends.
What is Roivant Sciences’s EPS estimate?
Roivant Sciences’s EPS estimate is -0.3.
How many shares outstanding does Roivant Sciences have?
Roivant Sciences has 715,701,100 shares outstanding.
What happened to Roivant Sciences’s price movement after its last earnings report?
Roivant Sciences reported an EPS of -$0.17 in its last earnings report, beating expectations of -$0.3. Following the earnings report the stock price went up 22.138%.
Which hedge fund is a major shareholder of Roivant Sciences?
Currently, no hedge funds are holding shares in ROIV
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Roivant Sciences Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$31.44 (13.62% Upside)
$31.44 (13.62% Upside)
Blogger Sentiment
Bullish
ROIV Sentiment 75%
Sector Average ―
Sector Average ―
Hedge Fund Trend
Decreased
By 12.4M Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $382.7M over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Negative
Last 7 Days ▼ 6.2%
Last 30 Days ▲ 0.5%
Last 30 Days ▲ 0.5%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
154.08%
12-Months-Change
Fundamentals
Return on Equity
-17.11%
Trailing 12-Months
Asset Growth
-9.79%
Trailing 12-Months
Company Description
Roivant Sciences
Roivant Sciences Ltd., a biopharmaceutical and healthcare technology company that researches and develops medicines. The company develops product candidates for the treatment of various therapeutics, including solid tumors, sickle cell diseases, hypophosphatasia, oncologic malignancies, psoriasis, atopic dermatitis, vitiligo, hyperhidrosis, acne, myasthenia gravis, warm autoimmune hemolytic anemia, thyroid eye diseases, sarcoidosis, and staph aureus bacteremia. The company was founded in 2014 and is based in London, the United Kingdom.
ROIV Company Deck
ROIV Earnings Call
Q3 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call presented a highly positive clinical development narrative — most notably a strong Phase II win for brepocitinib in cutaneous sarcoidosis with large effect sizes, supportive PROs and clean safety — together with multiple fully enrolled studies and a strong cash position. Key risks discussed include the small size and baseline imbalances of the CS trial (requiring Phase III confirmation), ongoing litigation (Moderna jury trial), high operating expenses and uncertainties around regulatory timelines, pricing and competition. On balance, the breadth of positive clinical results, enrollment momentum, and financial runway outweigh the execution and regulatory/legal risks.View all ROIV earnings summariesROIV Stock 12 Month Forecast
Average Price Target
$31.44
▲(13.62% Upside)
Technical Analysis
Ownership Overview
21.34% Insiders
14.09% Mutual Funds
1.02% Other Institutional Investors
50.92% Public Companies and
Individual Investors